Harmony Biosciences

Business

Harmony CFO's Complete Stock Sale Raises Eyebrows Amid Upbeat Revenue Forecasts

Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.

Business

Cogent Biosciences Gains Key FDA Designations for Bezuclastinib, Spotlighting GIST Treatment Potential

Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.

Business

FDA Grants Breakthrough Status to Cogent Biosciences' GIST Combo Therapy, Accelerating Path to Market

Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.

Business

IDEAYA Biosciences: A Buying Opportunity After the Pullback, or Priced for Perfection?

IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.

Business

China Approves Sciwind's Diabetes Drug Xianyida, Intensifying GLP-1 Market Competition

Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.

Business

BD Strikes Waters Deal and Advances Medical Plastics Recycling in Strategic Overhaul

Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.

Business

Boston Woman's Plea on The Ramsey Show Exposes Marital Strain Over Risky Real Estate Gambles

A Boston woman's call to a popular finance show reveals a marriage buckling under the weight of multi-million dollar real estate debt and conflicting risk appetites, highlighting how financial discord can threaten relationships.

Business

Three Global Stocks Trading at a Discount: Undervalued Picks for February 2026

Amid a market environment of stable rates and mixed sentiment, we highlight three companies—spanning biotech, gaming, and tech hardware—whose current share prices appear significantly below their estimated intrinsic value based on cash flow projections.

Business

IFF's Post-Earnings Crossroads: A Deep Dive into the Flavor Maker's Struggles

International Flavors & Fragrances (IFF) shares have lagged the broader market, raising questions about its turnaround strategy and long-term value proposition for investors.

Business

Starbucks CEO Hails Baristas' Stock Market Curiosity as Sign of Deeper Engagement Amid Union Tensions

CEO Brian Niccol says employees' questions about share prices reflect pride and care, as the coffee giant navigates workplace reforms and ongoing labor disputes.